Key result
Adrenomedullin shows therapeutic potential to regenerate blood vessels and control inflammation in cerebrovascular diseases.
Adrenomedullin is highlighted as a promising therapeutic candidate for vascular cognitive impairment and CADASIL due to its angiogenic and anti-inflammatory properties.
May warrant targeted research on adrenomedullin in vascular cognitive impairment; leaves clinical translation open without randomized trials.
Adrenomedullin (AM) is an endogenous peptide mainly secreted from endothelial cells, which has multiple physiological actions such as anti-inflammation, vasodilation, vascular permeability regulation and angiogenesis. Blood AM levels are upregulated in a variety of pathological states including sepsis, severe COVID-19, acute ischemic stroke and vascular cognitive impairment with white matter changes, likely serving as a compensatory biological defense response against infection and ischemia. AM is currently being tested in clinical trials for ulcerative colitis, Crohn's disease, severe COVID-19 for its anti-inflammatory properties and in ischemic stroke for its additional angiogenic action. AM has been proposed as a therapeutic option for vascular cognitive impairment as its arteriogenic and angiogenic properties are thought to contribute to a slowing of cognitive decline in mice after chronic cerebral hypoperfusion. As AM promotes differentiation of oligodendrocyte precursor cells into mature oligodendrocytes under hypoxic conditions, AM could also be used in the treatment of CADASIL, where reduced oxygen delivery is thought to lead to the death of hypoxia-prone oligodendrocytes. AM therefore holds potential as an innovative therapeutic drug, which may regenerate blood vessels, while controlling inflammation in cerebrovascular diseases.
No takes yet. Share an insight, caveat, or question.
Ihara et al. (2021) conducted a review in Vascular cognitive impairment. Adrenomedullin was evaluated. Adrenomedullin holds potential as an innovative therapeutic drug for regenerating blood vessels and controlling inflammation in cerebrovascular diseases such as vascular cognitive impairment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: